Date published: 2025-12-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

DnaJC12 Inhibitors

DnaJC12 inhibitors encompasses a diverse range of chemical entities that share the common ability to selectively hinder the activity of the DnaJC12 protein. DnaJC12 is a member of the DNAJ family, which acts as molecular chaperones to assist in the proper folding, assembly, and transport of proteins within cells. These inhibitors are designed to bind to specific regions of the DnaJC12 protein, often the active site or nearby allosteric sites, using various modes of interaction, including covalent and non-covalent bonding. The inhibition of DnaJC12 by these small molecules has profound effects on cellular processes that depend on its chaperone activity. By forming stable complexes with DnaJC12, these inhibitors disrupt its normal functioning. The structural perturbations induced by inhibitor binding can interfere with the chaperone's interactions with client proteins, preventing their correct folding, assembly, or transport. This disruption can trigger cellular responses aimed at restoring protein homeostasis, and it may also lead to the accumulation of misfolded or mislocalized proteins that could have implications for cellular health. The precise mechanisms by which DnaJC12 inhibitors exert their effects can vary. Some inhibitors may sterically hinder the interaction between DnaJC12 and its client proteins, while others might induce conformational changes in DnaJC12 that impede its chaperone function. Depending on the structural features of the inhibitor and its binding site on DnaJC12, the outcome of inhibition could differ, ranging from a complete loss of chaperone function to a partial impairment of its activity. The exploration of DnaJC12 inhibitors not only provides insights into the fundamental roles of DnaJC12 in cellular biology but also offers opportunities for understanding the broader significance of molecular chaperones in health and disease. By selectively modulating DnaJC12 activity, researchers can investigate the intricate network of cellular processes that rely on proper protein folding and trafficking.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Acalabrutinib

1420477-60-6sc-507392
250 mg
$255.00
(0)

Acalabrutinib inhibits DNAC12 by binding covalently to a cysteine residue within the active site of the enzyme. This prevents the transfer of phosphate groups to downstream substrates, disrupting the signaling cascade in B cells.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

Ibrutinib covalently binds to a specific cysteine residue in the active site of DNAC12. By irreversibly inhibiting the kinase activity, it interferes with B-cell receptor signaling and reduces cell proliferation in certain cancers.

Zanubrutinib

1691249-45-2sc-507434
5 mg
$360.00
(0)

Zanubrutinib selectively targets DNAC12 by forming a covalent bond with a cysteine residue at the active site. This prevents the phosphorylation of downstream substrates and inhibits cell growth and survival in B-cell malignancies.

Tirabrutinib

1351636-18-4sc-507435
10 mg
$135.00
(0)

Tirabrutinib targets DNAC12 by forming a covalent bond with a cysteine residue in its active site. This irreversible inhibition disrupts B-cell receptor signaling, leading to decreased proliferation and survival of B cells.

Spebrutinib

1202757-89-8sc-507524
100 mg
$375.00
(0)

Spebrutinib is a selective DNAC12 inhibitor that covalently binds to the active site of the kinase. This leads to the inhibition of B-cell receptor signaling and reduces the proliferation and survival of B-cell malignancies.